AOI Medical, Inc. announced that it has successfully completed surgical procedures on thirty (30) patients in a clinical trial with Ascendx Vertebral Compression Fracture (“VCF”) Reduction System (Ascendx) at six sites across the US. The board is pleased with the progress of the clinical trial and results to date; evaluation of clinical outcomes is ongoing. William J. Christy, CEO of AOI Medical, said: “The clinical program has gained momentum and we are pleased with our progress to date. The Ascendx system is designed to provide notable improvements in the way physicians traditionally treat VCFs. While all currently existing VCF procedures offer immediate pain relief to the patient, the Ascendx technology is specifically designed to provide a mechanical, repeatable cutting of cancellous bone and to deliver an even distribution of the bone cement.” Over time, these features may potentially provide benefits with respect to clinical outcomes, subject to ongoing clinical evaluation. On 12 March 2008, AOI received final approval from the FDA to commence a clinical trial for its Ascendx technology. The single arm trial of Ascendx will ultimately involve sixty (60) subjects in eight centers, with the primary end point being acute procedural success defined as successful device deployment, cement delivery, and device withdrawal. The data from the trial will be used as clinical support for the company’s 510(k) submission to the FDA in relation to Ascendx. The clinical trial is expected to complete its last patient enrollment and make its 510(k) submission to the FDA in mid-2009.